EUCTR2014-003239-21-NO进行中（未招募）1 期
An open-label, multi-center, expanded treatment protocol of oral panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and relapsed and refractory multiple myeloma
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 314
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Patient with diagnosis of multiple myeloma, based on IMWG definitions
- •- Patient requires retreatment
- •- Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of = 2
- •- Absolute neutrophil count (ANC) = 1.0 x 109 /L
- •- Platelet count = 100 x 109 /L
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 214
排除标准
- •- Patient has shown intolerance or has any contraindications to bortezomib, dexamethasone or panobinostat
- •- Patient is refractory to panobinostat
- •- Patient has grade = 2 peripheral neuropathy
- •- Patient taking any anti-cancer therapy concomitantly (bisphosphonates are permitted)
- •- Patient requires medication with a risk of prolonging the QT interval or inducing Torsades de pointes
研究者
相似试验
进行中（未招募）
1 期
An expanded treatment protocol of panobinostat in combination therapy for relapsed and relapsed and refractory (RR) cancer of plasma cells.Multiple myelomaEUCTR2014-003239-21-ATovartis Pharma Services AG200
进行中（未招募）
1 期
An expanded treatment protocol of panobinostat in combination therapy for relapsed and relapsed and refractory (RR) cancer of plasma cells.MedDRA version: 19.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Multiple myelomaEUCTR2014-003239-21-DEovartis Pharma Services AG200
进行中（未招募）
1 期
An expanded treatment protocol of panobinostat in combination therapy for relapsed and relapsed and refractory (RR) cancer of plasma cells.Multiple myelomaEUCTR2014-003239-21-SEovartis Pharma Services AG200
进行中（未招募）
不适用
Expanded Treatment Protocol of ruxolitinib in Polycythemia Vera patients who are HU resistant or intoleranthydroxyurea resistant or intolerant patients with polycythemia veraMedDRA version: 17.1Level: LLTClassification code 10036061Term: Polycythemia veraSystem Organ Class: 100000004864EUCTR2014-001309-42-SKovartis Pharma Services AG1,500
已完成
3 期
Expanded treatment protocol to find out if the drug LDK378 is safe in people who have a particular type of lung cancer called â??ALK positiveâ?? non-small cell lung cancerCTRI/2014/12/005250ovartis Healthcare Private Limited